drugset / Trial / NCT02570490
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
Timeline
- Start
- 2015-11
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Linezolid | Other / unclassified | 600 mg | Oral |
| Subject | sodium fusidate | Unknown | 600 mg | Oral |
Indications
No indication recorded.